Skip to main content

Sage Therapeutics, Inc. (SAGE)

NASDAQ: SAGE · IEX Real-Time Price · USD
40.65
-0.78 (-1.88%)
After-hours:Oct 25, 2021 6:33 PM EDT
41.43
0.01 (0.02%)
At close: Oct 25, 4:00 PM
Market Cap2.44B
Revenue (ttm)1.11B
Net Income (ttm)666.15M
Shares Out58.58M
EPS (ttm)11.84
PE Ratio3.50
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume321,589
Open41.15
Previous Close41.42
Day's Range40.75 - 41.85
52-Week Range39.77 - 98.39
Beta1.86
AnalystsBuy
Price Target79.32 (+91.5%)
Est. Earnings DateNov 2, 2021

About SAGE

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, bipolar depression, and generalized anxiety disorders; and SAGE-324, a compound that is in Phase II clinical ...

IndustryBiotechnology
IPO DateJul 18, 2014
CEOJeffrey Jonas
Employees298
Stock ExchangeNASDAQ
Ticker SymbolSAGE
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 21 analysts, the average rating for SAGE stock is "Buy." The 12-month stock price forecast is 79.32, which is an increase of 91.46% from the latest price.

Price Target
$79.32
(91.46% upside)
Analyst Consensus: Buy

News

Sage Therapeutics to Report Third Quarter 2021 Financial Results on Tuesday, November 2, 2021

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with de...

5 days ago - Business Wire

Sage Therapeutics and Biogen Announce Plans to Submit a New Drug Application (NDA) for Zuranolone to the U.S. Food & ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) today announced their plan to submit a New Drug Application (NDA) to the U.S. Food and Drug Admin...

Other symbols:BIIB
6 days ago - Business Wire

Top 3 undervalued US biotech stocks to buy

With the US Q3 earnings season just getting started, there are a few biotech stocks that present an exciting opportunity for value investors. Some of these stocks look significantly undervalued after a ...

Other symbols:REGNRPRX
1 week ago - Invezz

Sage Therapeutics and Biogen Announce Consistent Clinically Meaningful Data for Zuranolone Across the LANDSCAPE and N...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) today announced new data from the LANDSCAPE and NEST clinical development programs evaluating the...

Other symbols:BIIB
3 weeks ago - Business Wire

Sage Therapeutics Launches SageCitizen Social Impact Initiative

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics (Nasdaq: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilita...

3 weeks ago - Business Wire

Sage Therapeutics Appoints Chris Benecchi as Chief Commercial Officer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilita...

1 month ago - Business Wire

Why Sage Therapeutics Shares Are Trading Higher Today

Sage Therapeutics (NASDAQ:SAGE) shares are trading higher after the company announced it received Fast Track Designation for SAGE-718 or the treatment of Huntington's disease. Sage Therapeutics is curre...

1 month ago - Benzinga

Sage Therapeutics Receives Fast Track Designation for SAGE-718 for the Treatment of Huntington's Disease

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with deb...

1 month ago - Business Wire

Sage Therapeutics to Present at the Morgan Stanley Global Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with de...

1 month ago - Business Wire

7 Best Biotech Stocks to Buy in 2021 with Huge Upside

Biotech stocks are worth considering. Risk aside, big pharma firms can still produce big pharma returns at the end of the day.

2 months ago - InvestorPlace

These 3 Stocks Appear Underestimated by the Market

When searching for value opportunities, investors could be interested in the following stocks, since their prices are trading at a discount to the intrinsic value calculated by GuruFocus' earnings-based...

Other symbols:RUSHARUSHBVRTS
2 months ago - GuruFocus

Sage Therapeutics to Present at Upcoming August Investor Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with de...

2 months ago - Business Wire

Sage Therapeutics Drops Two Zuranolone Depression Trials Deemed Unnecessary For Approval

Tucked in the Q2 earnings release, Sage Therapeutics Inc (NASDAQ: SAGE) has terminated two long-suspended Phase 3 zuranolone trials in major depressive disorder (MDD). What Happened: After talks with th...

2 months ago - Benzinga

Sage Therapeutics, Inc. (SAGE) Reports Q2 Loss, Lags Revenue Estimates

Sage Therapeutics, Inc. (SAGE) delivered earnings and revenue surprises of -8.28% and -19.34%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Sage Therapeutics Announces Second Quarter 2021 Financial Results and Highlights Pipeline and Business Progress

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Today, Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people ...

2 months ago - Business Wire

Sage Therapeutics, Inc. (SAGE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Sage Therapeutics, Inc. (SAGE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

Sage Therapeutics to Report Second Quarter 2021 Financial Results on Tuesday, August 3, 2021

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with de...

3 months ago - Business Wire

Late-Stage Clinical Study Readouts Biotech Investors Should Watch

Several drugmakers have important clinical trial updates on the way.

Other symbols:BIIBNVSPFEQURE
3 months ago - The Motley Fool

Sage Therapeutics to Participate in Cowen's Psychedelics & Novel Mechanisms in Neuropsychiatry Summit

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with de...

3 months ago - Business Wire

These are the stocks seeing the most insider buying this week

Brian Sullivan brings you the top five stocks seeing the most insider buying action this week, on Worldwide Exchange with data from Insiderscore.com.

Other symbols:ASANCLREVAQSR
4 months ago - CNBC Television

Sage Therapeutics to Participate in SVB Leerink's 3rd Annual CNS Forum

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with de...

4 months ago - Business Wire

What Happened to Sage Therapeutics Stock?

Sage has been struggling for some time to bring its flagship antidepressant to the market.

4 months ago - The Motley Fool

Here's Why Sage Therapeutics Tanked This Week

The neuroscience-focused biotech company didn't give investors the result they wanted.

4 months ago - The Motley Fool

4 Undervalued Biotech Stocks That Belong On Every Investor's Buy List

Searching for undervalued biotech stocks? Here are 4 biotech stocks to buy for a mix of value and growth in any portfolio.

Other symbols:BIIBINVASIGA
4 months ago - InvestorPlace

Sage Stock Declines on Late-Stage Depression Study Data

Sage is developing zuranolone as a potential treatment for major depression disorder in late-stage studies.

Other symbols:BIIBNERVVTGN
4 months ago - Zacks Investment Research